Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05712356 · ClinicalTrials.gov registry record · Phase 2
A Study of LSTA1 When Added to Standard of Care Versus Standard of Care Alone in Patients With Advanced Solid Tumors
A Phase 2 study of Cholangiocarcinoma and Intrahepatic Cholangiocarcinoma, sponsored by Lisata Therapeutics.
- Active
- Registry status
- Phase 2
- Development phase
- 67
- Enrollment target
- 19
- Study locations
NCT05712356: Active Phase 2 study of Cholangiocarcinoma and Intrahepatic Cholangiocarcinoma, sponsored by Lisata Therapeutics.
NCT05712356 is a Phase 2 study of Cholangiocarcinoma and Intrahepatic Cholangiocarcinoma that is active but no longer recruiting, run by Lisata Therapeutics. The registered enrollment target is 67 participants, below the 385-participant average among 60 other Cholangiocarcinoma trials with a reported enrollment target (83% lower). The trial reports 19 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05712356, a Phase 2 study of Cholangiocarcinoma and Intrahepatic Cholangiocarcinoma, is active but no longer recruiting, sponsored by Lisata Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 67 participants
- Enrollment target
- 19
- Study locations
Study Summary
The goal of this clinical trial is to test a new drug plus standard treatment compared with standard treatment alone in patients with previously untreated cholangiocarcinoma or those that have progressed after first-line treatment for cholangiocarcinoma. The main questions it aims to answer are: * is the new drug plus standard treatment safe and tolerable * is the new drug plus standard treatment more effective than standard treatment
Primary Outcome
The National Cancer Institute Common Terminology Criteria for Adverse Events Version 5.0 (NCI CTCAE) will be used to grade the intensity of adverse events throughout the study
Conditions Studied
Interventions
- DRUG Cisplatin
- DRUG Gemcitabine
- DRUG FOLFOX regimen
- DRUG Durvalumab
- DRUG certepetide
Study Locations (19)
Arizona
- Banner MD Anderson Cancer Center - Gilbert
- Mayo Clinic Arizona - Phoenix
- University of Arizona Cancer Center - Tucson
Kentucky
- University of Kentucky Medical Center - Lexington
- Norton Cancer Institute, Downtown - Louisville
- Norton Cancer Institute, Audubon - Louisville
Kansas
- Alliance for Multispecialty Research - Merriam
- University of Kansas Cancer Center - Westwood
New York
- Northwell Health - Zuckerberg Cancer Center - Lake Success
- Stony Brook Cancer Center - Stony Brook
Texas
- University of Texas Southwestern Medical Center - Dallas
- The University of Texas MD Anderson Cancer Center - Houston
Florida
- Moffitt Cancer Center - Tampa
Minnesota
- Mayo Clinic Rochester - Rochester
North Carolina
- FirstHealth of the Carolinas, Inc. - Pinehurst
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 67 participants |
| Start Date | 2023-08-24 |
| Est. Completion | 2030-03 |
| Phase | Phase 2 |
What the registry record for NCT05712356 still lists
NCT05712356 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 67 participants, a relatively small participant target, below the 385-participant average among 60 other Cholangiocarcinoma trials with a reported enrollment target (83% lower).
The record links to 6 conditions, with Cholangiocarcinoma appearing as the primary indexed condition, and to 5 interventions - of which Cisplatin is the first listed.
NCT05712356 lists 19 locations in 12 states (Arizona, Kentucky, Kansas).
Frequently Asked Questions
What is clinical trial NCT05712356 about?
NCT05712356 is a clinical study titled "A Study of LSTA1 When Added to Standard of Care Versus Standard of Care Alone in Patients With Advanced Solid Tumors". The goal of this clinical trial is to test a new drug plus standard treatment compared with standard treatment alone in patients with previously untreated cholangiocarcinoma or those that have progressed after first-line treatment for cholangiocarcinoma. The main questions it aims to answer are: *...
What is the current status of trial NCT05712356?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 67 participants. The study started on 2023-08-24. Estimated completion is 2030-03.
What conditions does trial NCT05712356 study?
This clinical trial studies the following conditions: Cholangiocarcinoma, Intrahepatic Cholangiocarcinoma, Bile Duct Cancer, Gallbladder Cancer, Gallbladder Carcinoma.
What interventions are being tested in trial NCT05712356?
The interventions under investigation include: Cisplatin (DRUG), Gemcitabine (DRUG), FOLFOX regimen (DRUG), Durvalumab (DRUG), certepetide (DRUG).
Who is sponsoring clinical trial NCT05712356?
This trial is sponsored by Lisata Therapeutics, which has 12 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05712356 being conducted?
This trial has 19 study locations across Arizona, Florida, Kansas, Kentucky, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cholangiocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05712356's enrollment target sits among peer trials
67 37th of 60 higher than 24 of 60 other Cholangiocarcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cholangiocarcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of Gemcitabine, Cisplatin, AB680 and AB122 During First Line Treatment of Advanced Biliary Tract Cancers (QUIC)
RECRUITING · Phase 2
-
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Biliary Tract Cancers
RECRUITING · Phase 2
-
PDS01ADC in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer, Intrahepatic Cholangiocarcinoma, or Metastatic Adrenocortical Carcinoma
RECRUITING · Phase 2
-
A Single-Arm Study of Pembrolizumab With Gemcitabine and Cisplatin as Perioperative Therapy for Potentially Resectable Intrahepatic Cholangiocarcinoma
RECRUITING · Phase 2
-
Y-90 With Durvalumab/Gem/Cis in Intrahepatic Cholangio
RECRUITING · Phase 2
-
Trifluridine/Tipiracil + Oxaliplatin in Participants With Advanced or Metastatic Biliary Tract Cancer
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03213002 · 67 participants · Phase 1
Oral Capecitabine and Temozolomide (CAPTEM) for Newly Diagnosed GBM
- NCT04115163 · 67 participants · Phase 2
Biologically Optimized Infusion Schedule of Gemcitabine and Nab-Paclitaxel for the Treatment of Metastatic Pancreatic Cancer
- NCT04315324 · 67 participants · Phase 1
Study to Test OBI-3424 in Patients With T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LBL)
- NCT04532424 · 67 participants · NA
Transcranial Magnetic Stimulation for Restricted and Repetitive Behavior in ASD
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI